SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    M.W.M. Schellings, K. Boonen, E.M.H. Schmitz, F. Jonkers, D.J. van den Heuvel, A. Besselaar, J.G.E. Hendriks, D. van de Kerkhof, Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery, Thrombosis Research, 2016, 139, 128

    CrossRef

  2. 2
    Ming-Hui Dong, Hai-Feng Chen, Yu-Jie Ren, Fang-Ming Shao, Molecular modeling studies, synthesis and biological evaluation of dabigatran analogues as thrombin inhibitors, Bioorganic & Medicinal Chemistry, 2016, 24, 2, 73

    CrossRef

  3. 3
    Meyler's Side Effects of Drugs, 2016,

    CrossRef

  4. 4
    Meyler's Side Effects of Drugs, 2016,

    CrossRef

  5. 5
    A. Enriquez, G. Y. H. Lip, A. Baranchuk, Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants, Europace, 2015,

    CrossRef

  6. 6
    Sebastian M Schellong, Dabigatran for the treatment of venous thromboembolism, Expert Review of Hematology, 2015, 8, 4, 413

    CrossRef

  7. 7
    Mei-Lin Li, Yu-Jie Ren, Ming-Hui Dong, Wei-Xin Ren, Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors, European Journal of Medicinal Chemistry, 2015, 96, 122

    CrossRef

  8. 8
    Lucia Terzuoli, Antonella Silvietti, Carlo Scapellato, Brunetta Porcelli, Roberto Cappelli, Determinazione dei farmaci anticoagulanti orali diretti in regime di urgenza, La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine, 2015, 11, 3, 157

    CrossRef

  9. 9
    Eman G. Nouman, Medhat A. Al-Ghobashy, Hayam M. Lotfy, Development and validation of LC–MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma, Journal of Chromatography B, 2015, 989, 37

    CrossRef

  10. 10
    Muhammed Sherid, Humberto Sifuentes, Samian Sulaiman, Salih Samo, Husein Husein, Ruth Tupper, Charles Spurr, Subbaramiah Sridhar, Gastrointestinal Bleeding with Dabigatran, a Comparative Study with Warfarin: A Multicenter Experience, The Korean Journal of Gastroenterology, 2015, 65, 4, 205

    CrossRef

  11. 11
    J. Nagadeep, P. Kamaraj, M. Arthanareeswari, Gradient RP-HPLC method for the determination of potential impurities in dabigatran etexilate in bulk drug and capsule formulations, Arabian Journal of Chemistry, 2015,

    CrossRef

  12. 12
    Kaisong Miao, Su Ni, Xianju Zhou, Nanwei Xu, Rongbin Sun, Chao Zhuang, Yuji Wang, Hidden blood loss and its influential factors after total hip arthroplasty, Journal of Orthopaedic Surgery and Research, 2015, 10, 1, 36

    CrossRef

  13. 13
    Samer Narouze, Honorio T. Benzon, David A. Provenzano, Asokumar Buvanendran, José De Andres, Timothy R. Deer, Richard Rauck, Marc A. Huntoon, Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications, Regional Anesthesia and Pain Medicine, 2015, 40, 3, 182

    CrossRef

  14. 14
    Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher, Andreas Clemens, Stefan Hantel, Martin Feuring, Jörg Kreuzer, Michael Huo, Richard J. Friedman, Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials, Thrombosis Journal, 2015, 13, 1

    CrossRef

  15. 15
    Partha Sardar, Saurav Chatterjee, Carl J. Lavie, Jay S. Giri, Joydeep Ghosh, Debabrata Mukherjee, Gregory Y.H. Lip, Risk of major bleeding in different indications for new oral anticoagulants: Insights from a meta-analysis of approved dosages from 50 randomized trials, International Journal of Cardiology, 2015, 179, 279

    CrossRef

  16. 16
    Yun-Chuan Mao, Shih-Tse Chen, Chung-Hwan Chen, Kun-Pin Hsieh, Kim-Hong Gan, Rivaroxaban in preventing venous thromboembolism after arthroplastic surgery in Taiwan, The Kaohsiung Journal of Medical Sciences, 2015, 31, 10, 534

    CrossRef

  17. 17
    Christian Wurnig, Andreas Clemens, Helmuth Rauscher, Eva Kleine, Martin Feuring, Reinhard Windhager, Josef Grohs, Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery, Thrombosis Journal, 2015, 13, 1

    CrossRef

  18. 18
    Meilin Li, Yujie Ren, Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-1H-benzoimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors, Archiv der Pharmazie, 2015, 348, 5
  19. 19
    G. Hossain Shahcheraghi, Mahzad Javid, Mohammad M. Arasteh, Thromboembolic disease after knee arthroplasty is rare in Southern Iran, Journal of Orthopaedics, 2015, 12, 2, 86

    CrossRef

  20. 20
    Jeremy S. Paikin, Jack Hirsh, Noel C. Chan, Jeffrey S. Ginsberg, Jeffrey I. Weitz, John W. Eikelboom, Timing the First Postoperative Dose of Anticoagulants, Chest, 2015, 148, 3, 587

    CrossRef

  21. 21
    Jan Beyer-Westendorf, Alexander T. Cohen, Manuel Monreal, Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data, European Heart Journal Supplements, 2015, 17, suppl D, D32

    CrossRef

  22. 22
    Paul K. L. Chin, Daniel F. B. Wright, David M. Patterson, Matthew P. Doogue, Evan J. Begg, A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time, British Journal of Clinical Pharmacology, 2014, 78, 3
  23. 23
    Csaba Gombár, Gyöngyi Horvath, Hristifor Gálity, Krisztián Sisák, Kálmán Tóth, Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty, Archives of Orthopaedic and Trauma Surgery, 2014, 134, 4, 449

    CrossRef

  24. 24
    Dabigatran in Patients with Mechanical Heart Valves, New England Journal of Medicine, 2014, 370, 4, 381

    CrossRef

  25. 25
    Jinyin Li, Jing Fang, Fanyi Zhong, Wenxue Li, Yuanjun Tang, Yungen Xu, Shilong Mao, Guorong Fan, Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate, intermediate metabolite and dabigatran in 50μL rat plasma and its application to pharmacokinetic study, Journal of Chromatography B, 2014, 973, 110

    CrossRef

  26. 26
    Raul Altman, New oral anticoagulants: are coagulation units still required?, Thrombosis Journal, 2014, 12, 1, 3

    CrossRef

  27. 27
    Stefania Antoniazzi, Driss Berdaï, Valentino Conti, Emilio Clementi, Francesco Salvo, Risk of major bleeding and the standard doses of dabigatran, European Journal of Internal Medicine, 2014, 25, 6, e73

    CrossRef

  28. 28
    Raul Altman, Claudio Gonzalez, Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs, Thrombosis Journal, 2014, 12, 1, 7

    CrossRef

  29. 29
    Paul A. Reilly, Thorsten Lehr, Sebastian Haertter, Stuart J. Connolly, Salim Yusuf, John W. Eikelboom, Michael D. Ezekowitz, Gerhard Nehmiz, Susan Wang, Lars Wallentin, The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients, Journal of the American College of Cardiology, 2014, 63, 4, 321

    CrossRef

  30. 30
    Guang Jian Liu, Yun Fu Wang, Ping You Chen, Wei Chang, Ming Li Tu, Li Ying Chang, Ping Cheng, Jie Luo, The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis, Drug Delivery, 2014, 21, 6, 436

    CrossRef

  31. 31
    Xavier Delavenne, Edouard Ollier, Thierry Basset, Laurent Bertoletti, Sandrine Accassat, Arnauld Garcin, Silvy Laporte, Paul Zufferey, Patrick Mismetti, A semi-mechanistic absorption model to evaluate drug–drug interaction with dabigatran: application with clarithromycin, British Journal of Clinical Pharmacology, 2013, 76, 1
  32. 32
    Jordan Knepper, Danielle Horne, Andrea Obi, Thomas W. Wakefield, A systematic update on the state of novel anticoagulants and a primer on reversal and bridging, Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2013, 1, 4, 418

    CrossRef

  33. 33
    Arne Ring, Karin Rathgen, Joachim Stangier, Paul Reilly, Andreas Clemens, Jeffrey Friedman, Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects, Clinical Drug Investigation, 2013, 33, 5, 333

    CrossRef

  34. 34
    Amy Sarma, Jeffrey E. Rossi, Jean M. Connors, Robert P. Giugliano, Dabigatran Excess: Case Report and Review of the Literature, Cardiology and Therapy, 2013, 2, 1, 111

    CrossRef

  35. 35
    Vida Hamidi, Tove Ringerike, Gunhild Hagen, Åsmund Reikvam, Marianne Klemp, NEW ANTICOAGULANTS AS THROMBOPROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT, International Journal of Technology Assessment in Health Care, 2013, 29, 03, 234

    CrossRef

  36. 36
    H. T. Benzon, M. J. Avram, D. Green, R. O. Bonow, New oral anticoagulants and regional anaesthesia, British Journal of Anaesthesia, 2013, 111, suppl 1, i96

    CrossRef

  37. 37
    I. Lisanne Holster, Vera E. Valkhoff, Ernst J. Kuipers, Eric T.T.L. Tjwa, New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis, Gastroenterology, 2013, 145, 1, 105

    CrossRef

  38. 38
    Tarek Y. El Ahmadieh, Salah G. Aoun, Marc R. Daou, Najib E. El Tecle, Rudy J. Rahme, Randall B. Graham, Joseph G. Adel, H. Hunt Batjer, Bernard R. Bendok, New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery, Journal of Clinical Neuroscience, 2013, 20, 10, 1350

    CrossRef

  39. 39
    Kirk A. Campbell, Martin Quirno, Michael S. Day, Eric J. Strauss, Preventing venous thromboembolism in major orthopaedic surgery, Current Orthopaedic Practice, 2013, 24, 3, 312

    CrossRef

  40. 40
    José H. de Gea-García, Manuel Álvarez, Genoveva Ruiz-Villa, José D. Jiménez-Parra, Síndrome de Wünderlich en un paciente anticoagulado con dabigatrán, Medicina Clínica, 2013, 141, 4, 184

    CrossRef

  41. 41
    Giulia Renda, Raffaele De Caterina, The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?, Vascular Pharmacology, 2013, 59, 3-4, 53

    CrossRef

  42. 42
    Saleh Rachidi, Ehab Saad Aldin, Charles Greenberg, Barton Sachs, Michael Streiff, Amer M Zeidan, The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery, Expert Review of Hematology, 2013, 6, 6, 677

    CrossRef

  43. 43
    Omar P. Haqqani, Mark D. Iafrati, Jane E. Freedman, Vascular Medicine: A Companion to Braunwald's Heart Disease, 2013,

    CrossRef

  44. 44
    C. Dansirikul, T. Lehr, K.-H. Liesenfeld, S. Haertter, A. Staab, A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery, Thrombosis and Haemostasis, 2012, 107, 4, 775

    CrossRef

  45. 45
    Nadia Rosencher, Pierre Albaladejo, A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk, Expert Opinion on Pharmacotherapy, 2012, 13, 2, 217

    CrossRef

  46. 46
    Paul A. Sibley, Richard J. Mandel, Atraumatic Acute Carpal Tunnel Syndrome in a Patient Taking Dabigatran, Orthopedics, 2012, 35, 8, e1286

    CrossRef

  47. 47
    S. Rohatagi, J. Mendell, H. Kastrissios, M. Green, M. Shi, I. Patel, D. E. Salazar, Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery, Thrombosis and Haemostasis, 2012, 108, 5, 887

    CrossRef

  48. 48
    Diana M. Sobieraj, Craig I. Coleman, Vanita Tongbram, Wendy Chen, Jennifer Colby, Soyon Lee, Jeffrey Kluger, Sagar Makanji, Ajibade Ashaye, C. Michael White, Comparative Effectiveness of Low-Molecular-Weight Heparins versus Other Anticoagulants in Major Orthopedic Surgery: A Systematic Review and Meta-analysis, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012, 32, 9
  49. 49
    Celeste B. Burness, Kate McKeage, Dabigatran Etexilate, Drugs, 2012, 72, 7, 963

    CrossRef

  50. 50
    R. J. Friedman, A. Kurth, A. Clemens, H. Noack, B. I. Eriksson, J. A. Caprini, Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: No increased risk of bleeding, Thrombosis and Haemostasis, 2012, 108, 1, 183

    CrossRef

  51. 51
    Judy W.M. Cheng, Huyen Vu, Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for the Management of Thromboembolic Disorders, Clinical Therapeutics, 2012, 34, 4, 766

    CrossRef

  52. 52
    S. Suárez Ortega, Dabigatrán: transformando el manejo del paciente anticoagulado, Revista Clínica Española, 2012, 212, 15

    CrossRef

  53. 53
    Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher, Andreas Clemens, Stefan Hantel, Andreas A. Kurth, Efficacy of delayed thromboprophylaxis with dabigatran: Pooled analysis, Thrombosis Research, 2012, 130, 6, 871

    CrossRef

  54. 54
    Masaki Watanabe, Fazeel M. Siddiqui, Adnan I. Qureshi, Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment, Neurocritical Care, 2012, 16, 1, 203

    CrossRef

  55. 55
    Lisa M. Baumann Kreuziger, Colleen T. Morton, David J. Dries, New anticoagulants, Journal of Trauma and Acute Care Surgery, 2012, 73, 4, 983

    CrossRef

  56. 56
    Alessandro Squizzato, New Prospective for the Management of Low-Risk Pulmonary Embolism: Prognostic Assessment, Early Discharge, and Single-Drug Therapy with New Oral Anticoagulants, Scientifica, 2012, 2012, 1

    CrossRef

  57. 57
    Anita Rajasekhar, Rebecca Beyth, Mark A. Crowther, Newer Anticoagulants in Critically Ill Patients, Critical Care Clinics, 2012, 28, 3, 427

    CrossRef

  58. 58
    M. Dicato, L. Plawny, Nouveaux anticoagulants : ont-ils déjà une place en oncologie ?, Oncologie, 2012, 14, 12, 659

    CrossRef

  59. 59
    Jawed Fareed, Indermohan Thethi, Debra Hoppensteadt, Old Versus New Oral Anticoagulants: Focus on Pharmacology, Annual Review of Pharmacology and Toxicology, 2012, 52, 1, 79

    CrossRef

  60. 60
    Joachim Stangier, Hildegard Stähle, Karin Rathgen, Willy Roth, Kathrin Reseski, Thomas Körnicke, Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin, The Journal of Clinical Pharmacology, 2012, 52, 2
  61. 61
    Luiz Eugênio Garcez Leme, Guilherme Turolla Sguizzatto, PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ORTHOPAEDIC SURGERY, Revista Brasileira de Ortopedia (English Edition), 2012, 47, 6, 685

    CrossRef

  62. 62
    Kwon-Duk Seo, Kyung-Yul Lee, Stroke Update 2011: New Antithrombotics, Korean Journal of Stroke, 2012, 14, 2, 62

    CrossRef

  63. 63
    ROGER A. WINKLE, R. HARDWIN MEAD, GREGORY ENGEL, MELISSA H. KONG, ROB A. PATRAWALA, The Use of Dabigatran Immediately After Atrial Fibrillation Ablation, Journal of Cardiovascular Electrophysiology, 2012, 23, 3
  64. 64
    Reed Garza, Michael H Huo, Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor, Expert Review of Cardiovascular Therapy, 2012, 10, 4, 423

    CrossRef

  65. 65
    Ola E. Dahl, Andreas A. Kurth, Nadia Rosencher, Herbert Noack, Andreas Clemens, Bengt I. Eriksson, Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement, International Orthopaedics, 2012, 36, 4, 741

    CrossRef

  66. 66
    Alexandra Wendler, Martin Wehling, Translatability scoring in drug development: eight case studies, Journal of Translational Medicine, 2012, 10, 1, 39

    CrossRef

  67. 67
    Andreas Clemens, Sebastian Haertter, Jeffrey Friedman, Martina Brueckmann, Joachim Stangier, Joanne van Ryn, Thorsten Lehr, Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification, Current Medical Research and Opinion, 2012, 28, 2, 195

    CrossRef

  68. 68
    Nadia Rosencher, Herbert Noack, Martin Feuring, Andreas Clemens, Richard J Friedman, Bengt I Eriksson, Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials, Thrombosis Journal, 2012, 10, 1, 9

    CrossRef

  69. 69
    Xavier Delavenne, Julie Moracchini, Silvy Laporte, Patrick Mismetti, Thierry Basset, UPLC MS/MS assay for routine quantification of dabigatran – A direct thrombin inhibitor – In human plasma, Journal of Pharmaceutical and Biomedical Analysis, 2012, 58, 152

    CrossRef

  70. 70
    Bhavana Bhagya Rao, R. Kalayarasan, Vikram Kate, N. Ananthakrishnan, Venous Thromboembolism in Cancer Patients Undergoing Major Abdominal Surgery: Prevention and Management, ISRN Vascular Medicine, 2012, 2012, 1

    CrossRef

  71. 71
    Wendy A Leong, Joseph A Caprini, Debra Hoppensteadt, Jawed Fareed, New Oral Anticoagulants, 2012,

    CrossRef

  72. 72
    Sam Schulman, Ammar Majeed, A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery, Drug Safety, 2011, 34, 6, 449

    CrossRef

  73. 73
    Arlene Tran, Angela Cheng-Lai, Dabigatran Etexilate, Cardiology in Review, 2011, 19, 3, 154

    CrossRef

  74. 74
    David R. P. Guay, Dabigatran Etexilate: A Possible Replacement for Heparinoids and Vitamin K Antagonists?, Hospital Practice, 2011, 39, 1, 105

    CrossRef

  75. 75
    Michael Ganetsky, Kavita M. Babu, Steven D. Salhanick, Robert S. Brown, Edward W. Boyer, Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant, Journal of Medical Toxicology, 2011, 7, 4, 281

    CrossRef

  76. You have free access to this content76
    Catherine J. Lee, Jack E. Ansell, Direct thrombin inhibitors, British Journal of Clinical Pharmacology, 2011, 72, 4
  77. 77
    Dennis Cada, Terri Levien, Danial Baker, Formulary Drug Reviews - Dabigatran, Hospital Pharmacy, 2011, 46, 3, 196

    CrossRef

  78. 78
    Job Harenberg, Martin Wehling, Future of Anticoagulant Therapy, Cardiovascular Therapeutics, 2011, 29, 5
  79. 79
    O. Cousin, C. Le Hello, M.-T. Barrellier, Incidence et distribution des thromboses veineuses des membres inférieurs diagnostiquées par écho-doppler au décours de prothèses de hanche, de genou et de fractures de hanche. Résultats portant sur 5981 explorations et 2123 thromboses en dix ans, Journal des Maladies Vasculaires, 2011, 36, 4, 243

    CrossRef

  80. 80
    Meyer M. Samama, Céline Guinet, Laboratory assessment of new anticoagulants, Clinical Chemistry and Laboratory Medicine, 2011, 49, 5

    CrossRef

  81. 81
    L. Bertoletti, P. Mismetti, Les nouveaux anticoagulants dans la maladie thrombo-embolique veineuse, Revue des Maladies Respiratoires, 2011, 28, 8, 1008

    CrossRef

  82. You have free access to this content82
    Rashid S. Kazmi, Bashir A. Lwaleed, New anticoagulants: how to deal with treatment failure and bleeding complications, British Journal of Clinical Pharmacology, 2011, 72, 4
  83. 83
    Elise S. Eerenberg, Josien van Es, Meertien K. Sijpkens, Harry R. Büller, Pieter W. Kamphuisen, New anticoagulants: Moving on from scientific results to clinical implementation, Annals of Medicine, 2011, 43, 8, 606

    CrossRef

  84. 84
    Charles Marc Samama, New anticoagulants: pharmacology and clinical studies, Wiener Medizinische Wochenschrift, 2011, 161, 3-4, 54

    CrossRef

  85. 85
    M. H. Huo, New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?, Thrombosis and Haemostasis, 2011, 106, 1, 45

    CrossRef

  86. 86
    Dhara Chaudhari, Rohit Bhuriya, Rohit Arora, Newer Anticoagulants as an Alternate to Warfarin in Atrial Fibrillation: A Changing Paradigm, American Journal of Therapeutics, 2011, 18, 1, e1

    CrossRef

  87. 87
    B. I. Eriksson, O. E. Dahl, M. H. Huo, A. A. Kurth, S. Hantel, K. Hermansson, J. M. Schnee, R. J. Friedman, Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*), Thrombosis and Haemostasis, 2011, 105, 4, 721

    CrossRef

  88. 88
    S. Müller, T. Wilke, M. Pfannkuche, I. Meßer, A. Kurth, H. Merk, F. Steinfeldt, D. Ganzer, C. Perka, Patientenpfade in der Thromboseprophylaxe nach Hüft- und Kniegelenkersatz, Der Orthopäde, 2011, 40, 7, 585

    CrossRef

  89. 89
    Sorrel E Wolowacz, Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery, Expert Review of Pharmacoeconomics & Outcomes Research, 2011, 11, 1, 9

    CrossRef

  90. 90
    S. Härtter, N. Yamamura, J. Stangier, P. A. Reilly, A. Clemens, Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate, Thrombosis and Haemostasis, 2011, 107, 2, 260

    CrossRef

  91. 91
    Santiago Redondo, Maria-Paz Martínez, Marta Ramajo, Jorge Navarro-Dorado, Abelardo Barez, Teresa Tejerina, Pharmacological basis and clinical evidence of dabigatran therapy, Journal of Hematology & Oncology, 2011, 4, 1, 53

    CrossRef

  92. 92
    Gregg Stashenko, Renato D. Lopes, David Garcia, John H. Alexander, Victor F. Tapson, Prophylaxis for venous thromboembolism: guidelines translated for the clinician, Journal of Thrombosis and Thrombolysis, 2011, 31, 1, 122

    CrossRef

  93. 93
    T. T. Horlocker, Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy, British Journal of Anaesthesia, 2011, 107, suppl 1, i96

    CrossRef

  94. 94
    Dario Bugada, Allegri Massimo, Zadra Nicola, Braschi Antonio, Borghi Battista, Grossi Paolo, Regional anesthesia and anticoagulant drugs: A survey of current Italian practice, European Journal of Pain Supplements, 2011, 5, S2
  95. 95
    Angelo C. Molinari, Paola Saracco, Valerio Cecinati, Maurizio Miano, Emilia Parodi, Massimo Grassi, Laura Banov, Domenico De Mattia, Paola Giordano, Venous thrombosis in children, Blood Coagulation & Fibrinolysis, 2011, 22, 5, 351

    CrossRef

  96. 96
    Honorio T. Benzon, Essentials of Pain Medicine, 2011,

    CrossRef

  97. 97
    Kathleen A Hazlewood, Christy M Weiland, Advances in oral anticoagulants: focus on dabigatran etexilate, Expert Review of Clinical Pharmacology, 2010, 3, 6, 727

    CrossRef

  98. 98
    R.J. Friedman, O.E. Dahl, N. Rosencher, J.A. Caprini, A.A. Kurth, C.W. Francis, A. Clemens, S. Hantel, J.M. Schnee, B.I. Eriksson, Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials, Thrombosis Research, 2010, 126, 3, 175

    CrossRef

  99. You have free access to this content99
    J. M. Walenga, C. Adiguzel, Drug and dietary interactions of the new and emerging oral anticoagulants, International Journal of Clinical Practice, 2010, 64, 7
  100. 100
    Ludovic Drouet, Le risque hémorragique des nouveaux anticoagulants oraux, Revue de Chirurgie Orthopédique et Traumatologique, 2010, 96, 1, 5

    CrossRef

  101. 101
    A. Godier, C.-M. Samama, Les nouveaux anticoagulants vont-ils changer la donne ?, Journal des Maladies Vasculaires, 2010, 35, 3, 146

    CrossRef

  102. 102
    Richard J. Friedman, New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty, Thrombosis, 2010, 2010, 1

    CrossRef

  103. 103
    P. MISMETTI, S. LAPORTE, New oral antithrombotics: a need for laboratory monitoring. For, Journal of Thrombosis and Haemostasis, 2010, 8, 4
  104. 104
    Meyer Michel Samama, Grigoris T. Gerotziafas, Newer anticoagulants in 2009, Journal of Thrombosis and Thrombolysis, 2010, 29, 1, 92

    CrossRef

  105. 105
    Thomas Wilke, Jörn Moock, Sabrina Müller, Matthias Pfannkuche, Andreas Kurth, Nonadherence in Outpatient Thrombosis Prophylaxis with Low Molecular Weight Heparins after Major Orthopaedic Surgery, Clinical Orthopaedics and Related Research®, 2010, 468, 9, 2437

    CrossRef

  106. 106
    Benjamin J. Wrigley, Gregory Y. H. Lip, Eduard Shantsila, Novel oral anticoagulants: the potential relegation of vitamin K antagonists in clinical practice, International Journal of Clinical Practice, 2010, 64, 7
  107. 107
    Rohtesh S Mehta, Novel oral anticoagulants. Part II: direct thrombin inhibitors, Expert Review of Hematology, 2010, 3, 3, 351

    CrossRef

  108. 108
    Catherine J. Lee, Gauri Badhwar, Jack E. Ansell, Oral IIa Inhibitors, Hematology/Oncology Clinics of North America, 2010, 24, 4, 739

    CrossRef

  109. 109
    Terese T. Horlocker, Denise J. Wedel, John C. Rowlingson, F. Kayser Enneking, Sandra L. Kopp, Honorio T. Benzon, David L. Brown, John A. Heit, Michael F. Mulroy, Richard W. Rosenquist, Michael Tryba, Chun-Su Yuan, Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy, Regional Anesthesia and Pain Medicine, 2010, 35, 1, 64

    CrossRef

  110. 110
    Lars C. Borris, Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty, Archives of Orthopaedic and Trauma Surgery, 2010, 130, 5, 583

    CrossRef

  111. 111
    D. Garcia, E. Libby, M. A. Crowther, The new oral anticoagulants, Blood, 2010, 115, 1, 15

    CrossRef

  112. 112
    Olusegun Osinbowale, Lobna Ali, Yung-Wei Chi, Venous Thromboembolism: A Clinical Review, Postgraduate Medicine, 2010, 122, 2, 54

    CrossRef

  113. 113
    Juan I. Arcelus, Joseph A. Caprini, Rutherford's Vascular Surgery, 2010,

    CrossRef

  114. 114
    A. Sautet, Conférences d'enseignement 2010, 2010,

    CrossRef

  115. 115
    Marc P. Bonaca, Philippe Gabriel Steg, Laurent J. Feldman, John F. Canales, James J. Ferguson, Lars Wallentin, Robert M. Califf, Robert A. Harrington, Robert P. Giugliano, Antithrombotics in Acute Coronary Syndromes, Journal of the American College of Cardiology, 2009, 54, 11, 969

    CrossRef

  116. 116
    M. R. LASSEN, O. E. DAHL, P. MISMETTI, D. DESTRÉE, A. G. G. TURPIE, AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose-ranging study, Journal of Thrombosis and Haemostasis, 2009, 7, 4
  117. 117
    Joachim Stangier, Karin Rathgen, Hildegard Stähle, Kathrin Reseski, Thomas Körnicke, Willy Roth, Coadministration of Dabigatran Etexilate and Atorvastatin, American Journal of Cardiovascular Drugs, 2009, 9, 1, 59

    CrossRef

  118. 118
    P. Mismetti, S. Laporte, Dabigatran : données pharmaco-cliniques, Annales Françaises d'Anesthésie et de Réanimation, 2009, 28, 9, S8

    CrossRef

  119. 119
    N. Rosencher, L. Bellamy, Dabigatran (Pradaxa®) : efficacité et tolérance, Annales Françaises d'Anesthésie et de Réanimation, 2009, 28, 9, S15

    CrossRef

  120. 120
    T. Michael Farley, Daniel Lewis, Tracy E. Macaulay, In the Pipeline: New Oral Anticoagulants for the Prevention of Venous Thromboembolism, Orthopedics, 2009, 32, 1, 35

    CrossRef

  121. 121
    T. Lecompte, M. Toussaint-Hacquard, J. Devignes, Les anticoagulants inhibiteurs directs de la thrombine, Annales Françaises d'Anesthésie et de Réanimation, 2009, 28, 9, S3

    CrossRef

  122. 122
    N. Rosencher, Les antithrombines directes, Journal des Maladies Vasculaires, 2009, 34, 2, 115

    CrossRef

  123. 123
    Raffaele De Caterina, Steen Dalby Kristensen, Giulia Renda, New anticoagulants for atrial fibrillation, Journal of Cardiovascular Medicine, 2009, 10, 6, 446

    CrossRef

  124. 124
    PL Gross, JI Weitz, New Antithrombotic Drugs, Clinical Pharmacology & Therapeutics, 2009, 86, 2
  125. 125
    Richard J. Friedman, New Oral Anticoagulants for Thromboprophylaxis After Total Hip or Knee Arthroplasty, Orthopedics, 2009, 32, 12/Supplement, 79

    CrossRef

  126. You have free access to this content126
    C. W. Khoo, K.-H. Tay, E. Shantsila, G. Y. H. Lip, Novel oral anticoagulants, International Journal of Clinical Practice, 2009, 63, 4
  127. 127
    Jennifer Carreiro Zikria, Jack Ansell, Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change, Current Opinion in Hematology, 2009, 16, 5, 347

    CrossRef

  128. 128
    Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery, The Journal of Arthroplasty, 2009, 24, 1, 1

    CrossRef

  129. 129
    Alejandro Lazo-Langner, Marc A. Rodger, Overview of Current Venous Thromboembolism Protocols in Hip Reconstruction, Orthopedic Clinics of North America, 2009, 40, 3, 427

    CrossRef

  130. 130
    Thomas Wilke, Patient Preferences for an Oral Anticoagulant after Major Orthopedic Surgery, The Patient: Patient-Centered Outcomes Research, 2009, 2, 1, 39

    CrossRef

  131. 131
    Geoffrey H. Westrich, Lindsey J. Bornstein, Prophylactic Modalities: Pharmacologic and Mechanical Compression, Seminars in Arthroplasty, 2009, 20, 4, 235

    CrossRef

  132. 132
    Michael D. Ezekowitz, Stuart Connolly, Amit Parekh, Paul A. Reilly, Jeanne Varrone, Susan Wang, Jonas Oldgren, Ellison Themeles, Lars Wallentin, Salim Yusuf, Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran, American Heart Journal, 2009, 157, 5, 805

    CrossRef

  133. 133
    Fred D. Cushner, Michael P. Nett, The Future of Thromboembolic Prophylaxis, Seminars in Arthroplasty, 2009, 20, 4, 251

    CrossRef

  134. 134
    Tromboprofilassi in chirurgia ortopedica: nuove prospettive, LO SCALPELLO-OTODI Educational, 2009, 22, 3, 194

    CrossRef

  135. 135
    Geno Merli, Alex C. Spyropoulos, Joseph A. Caprini, Use of Emerging Oral Anticoagulants in Clinical Practice, Annals of Surgery, 2009, 250, 2, 219

    CrossRef

  136. 136
    Meyler’s Side Effects of Cardiovascular Drugs, 2009,

    CrossRef

  137. 137
    Nahid Qushmaq, Jeffrey I. Weitz, New Therapeutic Agents in Thrombosis and Thrombolysis, 2009,

    CrossRef

  138. 138
    Juan V. Llau, María Luisa Sapena, Cristina López Forte, Raquel Ferrandis, Anestesia y enfermedad tromboembólica, Medicina Clínica, 2008, 131, 42

    CrossRef

  139. 139
    Renato D. Lopes, Jonathan P. Piccini, Elaine M. Hylek, Christopher B. Granger, John H. Alexander, Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician, Journal of Thrombosis and Thrombolysis, 2008, 26, 3, 167

    CrossRef

  140. 140
    Alex C. Spyropoulos, Brave new world: The current and future use of novel anticoagulants, Thrombosis Research, 2008, 123, S29

    CrossRef

  141. 141
    Mark Sanford, Greg L Plosker, Dabigatran Etexilate, Drugs, 2008, 68, 12, 1699

    CrossRef

  142. 142
    Ola E Dahl, Dabigatran etexilate: an oral direct thrombin inhibitor, Therapy, 2008, 5, 5, 685

    CrossRef

  143. 143
    Brooke E. Baetz, Sarah A. Spinler, Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008, 28, 11
  144. 144
    S.A. Kozek-Langenecker, Direkte Thrombininhibitoren, Der Anaesthesist, 2008, 57, 6, 597

    CrossRef

  145. 145
    M.L. Lozano, F. Marn, V. Roldn, F?rmacos antitromb?ticos en el ?mbito extrahospitalario, Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 2008, 10, 22, 1493

    CrossRef

  146. 146
    Edith A. Nutescu, Nancy L. Shapiro, Aimee Chevalier, New Anticoagulant Agents: Direct Thrombin Inhibitors, Cardiology Clinics, 2008, 26, 2, 169

    CrossRef

  147. 147
    C. W. Francis, New Issues in Oral Anticoagulants, Hematology, 2008, 2008, 1, 259

    CrossRef

  148. 148
    Sylvia Haas, New oral Xa and IIa inhibitors: updates on clinical trial results, Journal of Thrombosis and Thrombolysis, 2008, 25, 1, 52

    CrossRef

  149. 149
    Hitoshi Nishio, Masahiro Ieko, Toru Nakabayashi, New therapeutic option for thromboembolism – dabigatran etexilate, Expert Opinion on Pharmacotherapy, 2008, 9, 14, 2509

    CrossRef

  150. 150
    P. Marco, F. Tarín, J. Lucas, Nuevos anticoagulantes orales: características de las moléculas, mecanismos de acción, farmacocinéticas y farmacodinámicas, Medicina Clínica, 2008, 131, 66

    CrossRef

  151. 151
    T. Wilke, K. Neumann, U. Klapper, I. Meßer, A. Werner, U. Seidel, D. Röleke, Orale Antikoagulation bei Hüft- und Kniegelenkersatzpatienten, Der Orthopäde, 2008, 37, 5, 448

    CrossRef

  152. 152
    Joachim Stangier, Hildegard Stähle, Karin Rathgen, Willy Roth, Kasra Shakeri-Nejad, Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment, The Journal of Clinical Pharmacology, 2008, 48, 12
  153. 153
    Joachim Stangier, Hildegard Stähle, Karin Rathgen, Reinhold Fuhr, Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects, Clinical Pharmacokinetics, 2008, 47, 1, 47

    CrossRef

  154. 154
    Michael R. Lassen, Ola Dahl, Patrick Mismetti, Dirk Zielske, Alexander G.G. Turpie, SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery, Journal of the American College of Cardiology, 2008, 51, 15, 1498

    CrossRef

  155. 155
    Aurangzeb Siddique, Eduard Shantsila, Gregory YH Lip, The search for new anticoagulants: dabigatran etexilate, Therapy, 2008, 5, 6, 793

    CrossRef

  156. 156
    Vladimir Dragalin, Valerii V. Fedorov, Yuehui Wu, Two-stage design for dose-finding that accounts for both efficacy and safety, Statistics in Medicine, 2008, 27, 25
  157. 157
    Job Harenberg, A worldwide yearly survey of new data and trends in adverse drug reactions and interactions, 2008,

    CrossRef

  158. 158
    B. I. ERIKSSON, A. G. G. TURPIE, M. R. LASSEN, M. H. PRINS, G. AGNELLI, P. KÄLEBO, M. L. GAILLARD, L MEEMS, A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery, Journal of Thrombosis and Haemostasis, 2007, 5, 8
  159. 159
    G. AGNELLI, S. HAAS, J. S. GINSBERG, K. A. KRUEGER, A. DMITRIENKO, J. T. BRANDT, A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement, Journal of Thrombosis and Haemostasis, 2007, 5, 4
  160. 160
    Deborah A Reynolds, Jonathan L Halperin, Anticoagulation in women with nonvalvular atrial fibrillation: insights from clinical trials, Women's Health, 2007, 3, 6, 673

    CrossRef

  161. 161
    D. J. QUINLAN, J. W. EIKELBOOM, O. E. DAHL, B. I. ERIKSSON, P. S. SIDHU, J. HIRSH, Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery, Journal of Thrombosis and Haemostasis, 2007, 5, 7
  162. 162
    Jeffrey I Weitz, Lori-Ann Linkins, Beyond heparin and warfarin: the new generation of anticoagulants, Expert Opinion on Investigational Drugs, 2007, 16, 3, 271

    CrossRef

  163. 163
    Bengt I Eriksson, Ola E Dahl, Nadia Rosencher, Andreas A Kurth, C Niek van Dijk, Simon P Frostick, Martin H Prins, Rohan Hettiarachchi, Stefan Hantel, Janet Schnee, Harry R Büller, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, The Lancet, 2007, 370, 9591, 949

    CrossRef

  164. 164
    Michael D. Ezekowitz, Paul A. Reilly, Gerhard Nehmiz, Timothy A. Simmers, Rangadham Nagarakanti, Kambiz Parcham-Azad, K. Erik Pedersen, Dominick A. Lionetti, Joachim Stangier, Lars Wallentin, Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study), The American Journal of Cardiology, 2007, 100, 9, 1419

    CrossRef

  165. 165
    Qing Ma, Development of oral anticoagulants, British Journal of Clinical Pharmacology, 2007, 64, 3
  166. 166
    Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl, Sylvia Haas, Menno V. Huisman, Ajay K. Kakkar, Frank Misselwitz, Eva Muehlhofer, Peter Kälebo, Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement, Thrombosis Research, 2007, 120, 5, 685

    CrossRef

  167. 167
    J. ANSELL, Factor Xa or thrombin: is factor Xa a better target?, Journal of Thrombosis and Haemostasis, 2007, 5,
  168. 168
    William E Wade, William J Spruill, Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Expert Review of Pharmacoeconomics & Outcomes Research, 2007, 7, 3, 227

    CrossRef

  169. 169
    Simon J McRae, John W  Eikelboom, Latest medical treatment strategies for venous thromboembolism, Expert Opinion on Pharmacotherapy, 2007, 8, 9, 1221

    CrossRef

  170. 170
    M.-M. Samama, G. Gerotziafas, Les nouveaux anticoagulants, Annales Pharmaceutiques Françaises, 2007, 65, 2, 85

    CrossRef

  171. 171
    Jess L. Thompson, Chad E. Hamner, D. Dean Potter, Matthew Lewin, Thoralf M. Sundt, Hartzell V. Schaff, Melagatran for thromboprophylaxis after mechanical valve implantation: Results in a heterotopic porcine model, The Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 2, 359

    CrossRef

  172. 172
    B. I. ERIKSSON, O. E. DAHL, N. ROSENCHER, A. A. KURTH, C. N. VAN DIJK, S. P. FROSTICK, P. KÄLEBO, A. V. CHRISTIANSEN, S. HANTEL, R. HETTIARACHCHI, J. SCHNEE, H. R. BÜLLER, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, Journal of Thrombosis and Haemostasis, 2007, 5, 11
  173. 173
    J M Leitner, B Jilma, F B Mayr, F Cardona, A O Spiel, C Firbas, K Rathgen, H Stähle, U Schühly, E U Graefe-Mody, Pharmacokinetics and Pharmacodynamics of the Dual FII/FX Inhibitor BIBT 986 in Endotoxin-induced Coagulation, Clinical Pharmacology & Therapeutics, 2007, 81, 6
  174. 174
    B. IBANEZ, G. VILAHUR, J. J. BADIMON, Plaque progression and regression in atherothrombosis, Journal of Thrombosis and Haemostasis, 2007, 5,
  175. 175
    Iñaki F. Trocóniz, Christiane Tillmann, Karl-Heinz Liesenfeld, Hans-Günter Schäfer, Joachim Stangier, Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery, The Journal of Clinical Pharmacology, 2007, 47, 3
  176. 176
    N. Rosencher, M.-P. Bonnet, D. I. Sessler, Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies, Anaesthesia, 2007, 62, 11
  177. 177
    K. A. BAUER, Targeted inhibition of coagulation: oral agents show promise in phase III trials, Journal of Thrombosis and Haemostasis, 2007, 5, 11
  178. You have free access to this content178
    Joachim Stangier, Karin Rathgen, Hildegard Stähle, Dietmar Gansser, Willy Roth, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects, British Journal of Clinical Pharmacology, 2007, 64, 3
  179. 179
    Natasa Ivanovic, Maarten Beinema, Jacobus RBJ Brouwers, Mark Naunton, Maarten J Postma, Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban, Expert Review of Pharmacoeconomics & Outcomes Research, 2007, 7, 1, 49

    CrossRef

  180. 180
    Stefan Kuhle, Alice Lau, Laszlo Bajzar, Patsy Vegh, Jacqueline Halton, Irene Cherrick, Ron Anderson, Sunil Desai, Patricia McCusker, John Wu, Thomas Abshire, Donald Mahoney, Lesley Mitchell, Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with l-asparaginase: an in vitro study, British Journal of Haematology, 2006, 134, 5
  181. 181
    Antonio Gómez-Outes, Patrizia Berto, Paolo Prandoni, Cost–effectiveness of bemiparin in the prevention and treatment of venous thromboembolism, Expert Review of Pharmacoeconomics & Outcomes Research, 2006, 6, 3, 249

    CrossRef

  182. 182
    Karl-Heinz Liesenfeld, Hans G. Schäfer, Iñaki F. Trocóniz, Christiane Tillmann, Bengt I. Eriksson, Joachim Stangier, Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis, British Journal of Clinical Pharmacology, 2006, 62, 5
  183. 183
    Ángel Cequier, Jaume Maristany, Joan-Antoni Gómez-Hospital, Emili Iráculis, Francesc Jara, Enric Esplugas, Inhibidores directos de la trombina en el intervencionismo coronario percutáneo. Bivalirudina, Revista Española de Cardiología Suplementos, 2006, 6, 8, 18H

    CrossRef

  184. 184
    Heng Joo Ng, Mark A. Crowther, New Anti-thrombotic Agents: Emphasis on Hemorrhagic Complications and Their Management, Seminars in Hematology, 2006, 43, S77

    CrossRef

  185. 185
    Edith A. Nutescu, Nancy L. Shapiro, Aimee Chevalier, New Anticoagulant Agents: Direct Thrombin Inhibitors, Clinics in Geriatric Medicine, 2006, 22, 1, 33

    CrossRef

  186. You have free access to this content186
    CHRISTIAN VON HEYMANN, HELGE SCHOENFELD, MICHAEL SANDER, CLAUDIA SPIES, New antithrombotics – pharmacologic profile and implications for anesthesia and surgery, Transfusion Alternatives in Transfusion Medicine, 2006, 8, 3
  187. 187
    Dagmar Kubitza, Sylvia Haas, Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases, Expert Opinion on Investigational Drugs, 2006, 15, 8, 843

    CrossRef

  188. 188
    Bengt I Eriksson, Daniel J Quinlan, Oral Anticoagulants in Development, Drugs, 2006, 66, 11, 1411

    CrossRef

  189. 189
    B. I. ERIKSSON, L. BORRIS, O. E. DAHL, S. HAAS, M. V. HUISMAN, A. K. KAKKAR, F. MISSELWITZ, P. KÄLEBO, Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement, Journal of Thrombosis and Haemostasis, 2006, 4, 1
  190. 190
    E. U. GRAEFE-MODY, U. SCHÜHLY, K. RATHGEN, H. STÄHLE, J. M. LEITNER, B. JILMA, Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa, Journal of Thrombosis and Haemostasis, 2006, 4, 7
  191. 191
    Shannon M. Bates, Jeffrey I. Weitz, The status of new anticoagulants, British Journal of Haematology, 2006, 134, 1
  192. 192
    Christopher J. Boos, Gregory Y.H. Lip, Ximelagatran: An eulogy, Thrombosis Research, 2006, 118, 3, 301

    CrossRef

  193. 193
    A. G. G. TURPIE, W. D. FISHER, K. A. BAUER, L. M. KWONG, M. W. IRWIN, P. KÄLEBO, F. MISSELWITZ, M. GENT, BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study, Journal of Thrombosis and Haemostasis, 2005, 3, 11
  194. 194
    Marcello Di Nisio, Saskia Middeldorp, Harry R. Büller, Direct Thrombin Inhibitors, New England Journal of Medicine, 2005, 353, 10, 1028

    CrossRef

  195. 195
    Jack Ansell, Long-Term Anticoagulation: The Prospects for Alternatives to Warfarin, Seminars in Vascular Surgery, 2005, 18, 3, 134

    CrossRef

  196. 196
    J. I. WEITZ, S. M. BATES, New anticoagulants, Journal of Thrombosis and Haemostasis, 2005, 3, 8
  197. 197
    Simon J McRae, Jeffrey S Ginsberg, New anticoagulants for venous thromboembolic disease, Current Opinion in Cardiology, 2005, 20, 6, 502

    CrossRef

  198. 198
    Joachim Stangier, Bengt I. Eriksson, Ola E. Dahl, Lennart Ahnfelt, Gerhard Nehmiz, Hildegard Stähle, Karin Rathgen, Robbyna Svärd, Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement, The Journal of Clinical Pharmacology, 2005, 45, 5
  199. 199
    Robert M. Scarborough, Anjali Pandey, Xiaoming Zhang, Annual Reports in Medicinal Chemistry Volume 40, 2005,

    CrossRef

  200. 200
    Carlos A Salazar, Daniel del Aguila, Erika G Cordova, Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation, The Cochrane Library,
  201. 201
    Carlos A Salazar, German Malaga, Giuliana Malasquez, Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement, The Cochrane Library,
  202. 202
    Jawed Fareed, Evi Kalodiki, Debra Hoppensteadt, Management of Thrombotic Disorders,
  203. 203
    Rickard E. Malmström, New Anticoagulants: Focus on Currently Approved Oral Factor Xa and Factor IIa Inhibitors,
  204. 204
    Steen Husted, Lars Wallentin, Oral Direct Thrombin Inhibitors and Oral Factor Xa Inhibitors,